A Trial of Compliance Therapy in Outpatients With Schizophrenia or Schizoaffective Disorder
J Clin Psychiatry 2005;66(8):997-1001
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: To evaluate the efficacy of
compliance therapy when delivered to outpatients with
schizophrenia or schizoaffective disorder.
Method: Thirty patients with schizophrenia or
schizoaffective disorder (DSM-IV criteria) were recruited from
urban psychiatric outpatient clinics in an open trial of
compliance therapy. Compliance therapy is a
cognitive/psychoeducational approach consisting of 4 to 6
sessions lasting 30 to 60 minutes each. The primary outcome was
electronically measured antipsychotic medication adherence.
Adherence data were analyzed for effects during an initial
treatment period (month -1 to month +1) and a subsequent 5-month
follow-up period. Secondary outcome measures included clinician
and patient ratings of adherence, symptoms, insight, and
attitudes to medication treatment. Data were collected from
August 2001 to January 2004.
Results: Compliance therapy was not associated
with improvements in antipsychotic medication adherence. Patient
ratings of adherence improved during the month -1 to month +1
period, but not in the subsequent 5-month follow-up. A diagnosis
of schizoaffective disorder was associated with poorer adherence
than was a diagnosis of schizophrenia during the month -1 to
month +1 period. A higher degree of insight at baseline (end of
month -1) was associated with greater adherence in the 5-month
follow-up period. Symptoms, insight, and attitudes to medication
treatment did not change significantly during the study.
Conclusion: In this uncontrolled trial,
outpatients with schizophrenia or schizoaffective disorder did
not benefit from compliance therapy.